insights_auto
Why is ABVX down 2.33%?
Dive Deeperchevron_right
ABVX:NASDAQ
Abivax SA
$92.88
arrow_downward
-2.33%(-2.22) 1D
$92.80
arrow_downward
-0.09% (-0.080)bedtimeAfter hours
Closed: Oct 2, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
$95.82
High
$95.82
Low
$92.58
Mkt. cap
7.20B
Avg. vol.
1.27M
Volume
644.38K
52-wk high
$148.83
52-wk low
$69.81
Shares outstanding
87.53M
No. of employees
98
Open
$95.82
High
$95.82
Low
$92.58
Mkt. cap
7.20B
Avg. vol.
1.27M
Volume
644.38K
52-wk high
$148.83
52-wk low
$69.81
Shares outstanding
87.53M
No. of employees
98
News stories
From web sources and news partners
MarketBeat
·
3 days ago
Abivax (NASDAQ:ABVX) Stock Price Down 5.1% - Should You Sell?
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
FoundedDec 4, 2013
Headquarters-
SectorBiotechnology
Websiteabivax.com